Sen. Tammy Baldwin (D-Wis.) is demanding the four largest manufacturers of inhalers to stop improperly listing patents in a Food and Drug Administration (FDA) database, a practice that can delay lower-cost generics from coming to market. In letters sent Monday to AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK) and Teva, Baldwin called on the companies to remove their improperly listed patents from the FDA’s Orange Book, the federal database where patent and exclusivity information for FDA-approved drugs is listed. When a pharmaceutical company lists a patent in the Orange Book, it blocks the approval of competing drug products for up to 30 months. As a result, drug compan
Hence then, the article about baldwin calls on drug companies to stop gaming patents for asthma inhalers was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Baldwin calls on drug companies to stop gaming patents for asthma inhalers )